MedTrace Logo

Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia

NCT06973356 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-08-08

No results posted yet for this study

Summary

This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of relapsed and refractory immune thrombocytopenia. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19/BCMA CAR gene vector injection

Conditions

  • Immune Thrombocytopenia (ITP)

Interventions

DRUG

Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.

Description: A single intravenous infusion of anti-CD19/BCMA CAR gene vector injection(dose-escalating infusion of 1.0-4.0 x10\^6 TU/kg）.

Sponsors & Collaborators

  • Anhui Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • bing xing wang, M.D · The First Affiliated Hospital of University of Science and Technology of China

  • cheng chang zheng, M.D · The First Affiliated Hospital of University of Science and Technology of China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-16
Primary Completion
2029-06-30
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06973356 on ClinicalTrials.gov